BioSpace

Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’

Sanofi has discontinued an early-stage STAT6 degrader program licensed from Nurix Therapeutics, a decision analysts say is related to the asset itself or Sanofi’s strategic reprioritization rather than the drug class more broadly.

By BioSpace

1 min read
Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights